Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) Financial Ratios
2 years of historical data (2024–2025) · Financial Services · Shell Companies
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
0.96
+3% vs avg
5yr avg: 0.94
30Y Low0.9·High0.9
ROE
5.1%
+0% vs avg
5yr avg: 5.1%
30Y Low5%·High5%
Debt/EBITDA
N/A
—
5yr avg: 902.35
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
DMAA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Drugs Made In America Acquisition Corp. Ordinary Shares trades at 56.0x earnings, roughly in line with its 5-year average of 54.6x, sitting at the 100th percentile of its historical range. Compared to the Financial Services sector median P/E of 14.2x, the stock trades at a premium of 295%.
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Market Cap | $359M | $218M | — |
| Enterprise Value | $359M | $218M | — |
| P/E Ratio → | 56.00 | 54.60 | — |
| P/S Ratio | — | — | — |
| P/B Ratio | 0.96 | 0.94 | — |
| P/FCF | — | — | — |
| P/OCF | — | — | — |
P/E links to full P/E history page with 30-year chart
DMAA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| EV / Revenue | — | — | — |
| EV / EBITDA | — | — | — |
| EV / EBIT | — | — | — |
| EV / FCF | — | — | — |
DMAA Profitability
Margins and return-on-capital ratios measuring operating efficiency
ROE of 5.1% is modest, trailing the sector median of 8.9%.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Gross Margin | — | — | — |
| Operating Margin | — | — | — |
| Net Profit Margin | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| ROE | 5.1% | 5.1% | — |
| ROA | 5.0% | 5.0% | -87.0% |
| ROIC | -1.8% | -1.8% | — |
| ROCE | -2.4% | -2.4% | — |
DMAA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $6137 exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Debt / Equity | — | — | — |
| Debt / EBITDA | — | — | 902.35 |
| Net Debt / Equity | — | -0.00 | — |
| Net Debt / EBITDA | — | — | 661.00 |
| Debt / FCF | — | — | — |
| Interest Coverage | — | — | — |
Net cash position: cash ($6137) exceeds total debt ($0)
DMAA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.03x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 6.27x to 0.03x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Current Ratio | 0.03 | 0.03 | 6.27 |
| Quick Ratio | 0.03 | 0.03 | 6.27 |
| Cash Ratio | 0.02 | 0.02 | 1.70 |
| Asset Turnover | — | — | — |
| Inventory Turnover | — | — | — |
| Days Sales Outstanding | — | — | — |
DMAA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Drugs Made In America Acquisition Corp. Ordinary Shares does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 1.8% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Dividend Yield | — | — | — |
| Payout Ratio | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Earnings Yield | 1.8% | 1.8% | — |
| FCF Yield | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | — |
| Shares Outstanding | — | $21M | $9M |
Peer Comparison
Compare DMAA with 9 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 DMAAYou | $359M | 56.0 | — | — | — | — | 5.1% | -1.8% | — |
 HCAI | $10M | -0.2 | — | — | 6.2% | -322.7% | -262.3% | -71.3% | — |
 BRTX | $3M | -0.2 | — | — | 93.4% | -4350.1% | -320.5% | -343.7% | — |
 NUVB | $2B | -9.4 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 MRK | $317B | 17.6 | 12.0 | 25.7 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 PFE | $138B | 17.9 | 10.0 | 15.2 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 ABBV | $444B | 106.1 | 18.0 | 24.9 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 BMY | $117B | 16.7 | 9.3 | 9.1 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 LLY | $1.1T | 52.6 | 37.6 | 127.1 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 AMGN | $193B | 25.2 | 15.1 | 23.9 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
| Financial Services Median | — | 14.2 | 11.2 | 11.4 | 64.0% | 20.0% | 8.9% | 5.3% | 4.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 2 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
DMAA — Frequently Asked Questions
Quick answers to the most common questions about buying DMAA stock.
What is Drugs Made In America Acquisition Corp. Ordinary Shares's P/E ratio?
Drugs Made In America Acquisition Corp. Ordinary Shares's current P/E ratio is 56.0x. The historical average is 54.6x. This places it at the 100th percentile of its historical range.
What is Drugs Made In America Acquisition Corp. Ordinary Shares's ROE?
Drugs Made In America Acquisition Corp. Ordinary Shares's return on equity (ROE) is 5.1%. The historical average is 5.1%.
Is DMAA stock overvalued?
Based on historical data, Drugs Made In America Acquisition Corp. Ordinary Shares is trading at a P/E of 56.0x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.